VERU Veru Inc.

3.28
+0.07  (+2%)
Previous Close 3.21
Open 3.12
Price To Book 7.29
Market Cap 213,834,270
Shares 65,193,375
Volume 154,805
Short Ratio
Av. Daily Volume 382,240
Stock charts supplied by TradingView

NewsSee all news

  1. Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug

    --VERU-111 Targeting Men with Metastatic Castration Resistant Prostate Cancer Who Have Also Become Resistant to Abiraterone or Enzalutamide-- --Phase 2 Study Results Expected by Calendar Year End— MIAMI, Feb.

  2. Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57%

    --Completion of VERU-111 Phase 1b Clinical Trial and Initiation of Phase 2 Prostate Cancer Clinical Trial in Q2 FY 2020-- --Zuclomiphene Expected to Enter Pivotal Phase 3 Clinical Trial for Treating Hot Flashes in Men

  3. Veru to Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call on February 12th

    MIAMI, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today

  4. Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020

    MIAMI , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today

  5. Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy

    -- Plans to Advance Zuclomiphene into Pivotal Phase 3 Clinical Trial in First Half of 2020 -- -- Potential to be First FDA-Approved Drug for ADT Induced Hot Flashes -- MIAMI, Jan. 13, 2020 (GLOBE NEWSWIRE) --

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to commence by early summer 2020.
Zuclomiphene citrate
Hot flashes
NDA filing due 2H 2020.
Tadalafil and Finasteride combo
Benign prostatic hyperplasia (BPH)
Phase 2 trial initiation announced February 26, 2020 with data due by the end of 2020.
VERU-111 (bisindole)
Castration Resistant Prostate Cancer
Phase 2 trial to be initiated in 2020.
VERU-100
Prostate cancer

Latest News

  1. Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug

    --VERU-111 Targeting Men with Metastatic Castration Resistant Prostate Cancer Who Have Also Become Resistant to Abiraterone or Enzalutamide-- --Phase 2 Study Results Expected by Calendar Year End— MIAMI, Feb.

  2. Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57%

    --Completion of VERU-111 Phase 1b Clinical Trial and Initiation of Phase 2 Prostate Cancer Clinical Trial in Q2 FY 2020-- --Zuclomiphene Expected to Enter Pivotal Phase 3 Clinical Trial for Treating Hot Flashes in Men

  3. Veru to Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call on February 12th

    MIAMI, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today

  4. Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020

    MIAMI , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today

  5. Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy

    -- Plans to Advance Zuclomiphene into Pivotal Phase 3 Clinical Trial in First Half of 2020 -- -- Potential to be First FDA-Approved Drug for ADT Induced Hot Flashes -- MIAMI, Jan. 13, 2020 (GLOBE NEWSWIRE) --

  6. Veru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th

    MIAMI, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today

  7. Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes

    -- Potential to be First FDA-Approved Drug for ADT induced Hot Flashes – -- Topline Clinical Data Anticipated Fall 2019 -- MIAMI, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer

  8. Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York

    MIAMI, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today

  9. Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month

    MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today